|
Thanks to SoCalBio Partner
| |
|
|
Thanks to SoCalBio Weekly Update Sponsor
|
Recommended Events
January 23 - 24, 2012
Computer History Museum, Silicon Valley
******************** 
|
Join SoCalBio
Join SoCalBio leaders to promote the biotech and device industries in Los Angeles, Orange County and neighboring communities for job creation and overall economic growth.
|  |
| Thanks to SoCalBio Media Partners
|
|
|
December 19, 2011 
|  Editor: Ahmed Enany
President & CEO
Southern California
Biomedical Council
enany@socalbio.org
www.socalbio.org
|
| Do You Know? | |
Companies utilizing the SoCalBio Group Purchasing Program enjoy significant savings on products and services procured through this program. Here are the actual savings generated from the SoCalBio-Office Depot program for office supplies and equipment:
|
Office Supplies Spend Range Under the SoCalBio-Office Depot Program
|
Average Savings Off List Price Under the SoCalBio-Office Depot Program
| |
>$500k
|
$765,218
| |
$250k - $500k
|
$319,731
| |
$100k - $250k
|
$134,868
| |
$50k - $100k
|
$82,801
| |
$25k - $50k
|
$43,360
| |
$10k - $25k
|
$19,687
| |
$1k - $10k
|
$4,876
| | <$1k |
$491
|
The savings represent average annual savings of the actual program participants in the BIO-VWR program. Results will vary based on individual company's Product Mix and Purchase Volume ... Learn more
|
Must Read
| |
Seed-Stage Venture Investing, 2nd Edition: An Insider's Guide to Start-Ups for Scientists, Engineers, and Investors
 Co-authorted by SoCalBio Board Member Jonathan Lasch, PhD, of AMI-USC, this Aspatore venture capital title takes a fresh look at the world of start-ups, focusing on life science and technology spin-outs from academic and biomedical research centers. This book provides a substantial update to the previous edition, explaining the current challenges of financing research-intensive academic spin-outs and offering new insights and advice about evaluating technology ... Find out more
|
| Biotech Growth in Los Angeles | |
LaSalle's Life Sciences Cluster Report Ranks Los Angeles Fourth in the US
 The report contends that Los Angeles' vast number of hospitals, universities and research facilities and its large college-educated population should help propel the region's growing biotechnology sector to complement its mature medical device presence ... Read more
|
| Meet New SoCalBio Member Companies | |
ResearchDx (Irvine)
 ResearchDx is a contract diagnostics organization (CDO) for the biopharmaceutical and diagnostic industries... ResearchDx will be represented in SoCalBio by its Co-founder and Principal Philip D. Cotter, PhD .... Learn more
Neumedicines (Pasadena)
 Neumedicines Inc. is a privately held drug discovery and development company focused on innovative protein therapies for the treatment of hematopoietic deficiencies and cancer .... Learn more
SMRT Therapeutics (Los Angeles)
 | |
Dr. Richard Gatti
|
SMRT is a UCLA spinoff and winner of the UCLA Business of Science Center's business plan competition held last September and sponsored by the law firm of Perkins Coie. SMRT seeks to develop small molecules for treating genetic diseases. These molecules were discovered at the laboratory of Dr. Richard Gatti, Professor of Pathology and Laboratory Medicine, Geffen School of Medicine at UCLA.
Fox Rothschild (Los Angeles)
 Fox Rothschild delivers a full range of legal services - from the traditional (Litigation, Corporate, Labor and Employment) to the emerging services (Intellectual Property and Tech and Venture Finance). The firm has more than 500 lawyers in 16 offices throughout the US. Fox Rothschild is represented in SoCalBio by attorney Lisa Karczewski ... Learn more
Siegal Consulting (Pasadena)
Siegal Consulting provides business development analysis, in-licensing and new product commercial analysis and planning based on international and US experience. The company is represented in SoCalBio by Its founder Carolyn Siegal .... Learn more
|
|
SBIR Reauthorization
| | SoCalBio Applauds the Reauthorization of the SBIR/STTR Program
 On Wednesday, December 14 Congress passed legislation to reauthorize the Small Business Innovation and Research (SBIR) and the Small Business Technology Transfer (STTR) programs that help innovative small businesses make products that will benefit the government and the private sector. The reauthorization includes many of the policy changes advocated by the Biotechnology Industry Organization in collaboration with many regional bioscience associations throughout the U.S. such as SoCalBio. The list includes:
- Raising the percentage that agencies would have to set aside for SBIR by 0.1% each year from FY 2014 through FY 2019 when it would be 3.2% more
- Raising the maximum amount of grant funding for awardee businesses in the program's guidelines for the first time since 1982, from $100,000 to $150,000 for Phase I and from $750,000 to $1 million for Phase II.
- allowing companies (at an agency's discretion) to skip phase I (limited to DoD, NIH, and ED) and apply to get phase II grants
- Adopting the Senate percentages for funds that can be awarded to businesses that are majority-owned by multiple venture capital firms, hedge funds, or private equity firms: 25% of SBIR funds from NIH, DOE, and NSF and 15% for all other agencies.
Come to the 2012 SoCalBio Government Grant Funding Workshop on June 8, 8 am to 5 pm, at UCLA Faculty Center to sharpen your grant-writing skills and take advantage of the new SBIR/STTR provisions
|
|
Executive Changes
| | Amgen CEO Sharer, R&D Chief Perlmutter Stepping Down
 Kevin W. Sharer, chairman and chief executive officer of Amgen (photo right) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen. To facilitate an orderly transition process, Sharer will step down as CEO effective May 23, 2012, and remain as chairman of the Company's Board of Directors until December 31, 2012,  at which time he will retire from the Board and from the Company.... R&D chief Roger Perlmutter (photo right) will retire as executive vice president of research and development effective February 12, 2012. Dr. Perlmutter will then work with Amgen as a consultant to aid in the transition until February, 2013 ... Read press release
|
|
M&A
| | Valeant Makes a Hostile Bid to Acquire Ista Pharmaceuticals
Valeant Pharmaceuticals International Inc. is making a hostile bid to acquire Ista Pharmaceuticals Inc. for $6.50 per share in cash, or $314 million - the Canadian company's latest attempt to buy the eye-disease drug developer. The offer, announced Friday, is a 67 percent premium over Ista's closing stock price of $3.89 on Thursday ... Read more |
|
Arbitration
| | MannKind Resolves All Claims in Arbitration with Former Employee
MannKind Corporation announced that it reached a final resolution of the arbitration proceedings initiated by John Arditi, MannKind's former Senior Director - GCP - Regulatory Affairs. During his employment with MannKind, Mr. Arditi played a key role in preparing clinical sites for FDA inspection and was responsible for the company's GCP compliance audit program ... Read more
|
|
People on the Move
| | Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors
 "Mike's knowledge and experience in drug development will be instrumental as we progress our lead candidates through clinical development," said Dr. Christopher Anzalone (photo right), President and Chief Executive Officer of Arowhead. "In addition, his expertise in strategic business development transactions and product assessment will be important as we continue to execute on our partnership and broader business strategies" ... Read more
|
Jobs Available
| |
Advanced Bionics (Sylmar & Valencia)
- Click here to see a list of 37 available engineering, manufacturing, clinical, quality and sales jobs at Advanced Bionics
Equipois (Los Angeles)
Neumedicines (Pasadena)
Chromologic (Pasadena)
|
|
| About SoCalBio |
 SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
|
|
